Market Closed -
Bombay S.E.
06:00:50 2024-05-31 am EDT
5-day change
1st Jan Change
475.2
INR
-2.08%
-3.23%
-2.84%
Sales 2024
25.29B
303M
Sales 2025 *
27.64B
331M
Capitalization
43.68B
524M
Net income 2024
1.71B
20.55M
Net income 2025 *
2.38B
28.47M
EV / Sales 2024
1.58
x
Net cash position
2024
*
-
0
Net cash position
2025
*
-
0
EV / Sales 2025 *
1.58
x P/E ratio 2024
23.4
x
P/E ratio 2025 *
18.6
x
Employees
1,003
Yield 2024 *
0.99%
Yield 2025 *
1.35%
Free-Float
36.63%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Transcript : Aarti Drugs Limited, Q4 2024 Earnings Call, May 06, 2024
May. 06
Aarti Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024
May. 03
CI
Aarti Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2024
May. 03
CI
Aarti Drugs Limited Announces Executive Cessation
Mar. 29
CI
Aarti Drugs Begins Manufacturing Dermatology Products in Tarapur, India Facility
Jan. 30
MT
Aarti Drugs Limited Initiates Commercial Production of Dermatology Product At New Facility in Tarapur, Maharashtra
Jan. 30
CI
Transcript : Aarti Drugs Limited, Q3 2024 Earnings Call, Jan 25, 2024
Jan. 25
Aarti Drugs Limited Announces Interim Dividend for the Financial Year 2023- 24
Jan. 24
CI
Aarti Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Jan. 24
CI
Transcript : Aarti Drugs Limited, Q2 2024 Earnings Call, Oct 20, 2023
23-10-20
Aarti Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
23-10-19
CI
Tranche Update on Aarti Drugs Limited's Equity Buyback Plan announced on July 21, 2023.
23-08-28
CI
Aarti Drugs Limited's Equity Buyback announced on July 21, 2023, has closed with 665,000 shares, representing 0.72% for INR 598.5 million.
23-08-16
CI
Aarti Drugs Clocks Gains in Fiscal Q1 Consolidated Profit
23-07-24
MT
Transcript : Aarti Drugs Limited, Q1 2024 Earnings Call, Jul 24, 2023
23-07-24
More news
1 day -2.08%
1 week -3.23%
1 month -5.83%
3 months -4.46%
6 months -2.22%
Current year -2.84%
More quotes
Managers
Title Age Since
Chief Executive Officer
76
85-01-04
Director of Finance/CFO
41
12-07-05
Compliance Officer
-
19-04-22
Members of the board
Title Age Since
Chief Executive Officer
76
85-01-04
Director/Board Member
61
87-01-01
Director/Board Member
60
95-09-14
More insiders
Date
Price
Change
Volume
24-05-31
475.2
-2.08%
7,505
24-05-30
485.2
+0.15%
4,893
24-05-29
484.5
-2.03%
5,668
24-05-28
494.6
+2.55%
66,407
24-05-27
482.2
-1.78%
5,938
Delayed Quote
Bombay S.E., May 31, 2024 at 06:00 am EDT
More quotes
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
More about the company
Last Close Price
475.2
INR
Average target price
542
INR
Spread / Average Target
+14.07%
Consensus
1st Jan change
Capi.
-2.84% 523M +40.73% 739B +32.83% 598B -6.30% 353B +15.15% 318B +4.05% 285B +15.00% 240B -5.52% 206B +6.17% 164B -0.45% 162B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1